Abstract
Alcohol use disorders (AUDs) are complex and developing effective treatments will require the combination of novel medications and cognitive behavioral therapy approaches. Epidemiological studies have shown there is a high correlation between alcohol consumption and tobacco use, and the prevalence of smoking in alcoholics is as high as 80% compared to about 30% for the general population. Both preclinical and clinical data provide evidence that nicotine administration increases alcohol intake and nonspecific nicotinic receptor antagonists reduce alcohol-mediated behaviors. As nicotine interacts specifically with the neuronal nicotinic acetylcholine receptor (nAChR) system, this suggests that nAChRs play an important role in the behavioral effects of alcohol. In this review, we discuss the importance of nAChRs for the treatment of AUDs and argue that the use of FDA approved nAChR ligands, such as varenicline and mecamylamine, approved as smoking cessation aids may prove to be valuable treatments for AUDs. We also address the importance of combining effective medications with behavioral therapy for the treatment of alcohol dependent individuals.
Keywords: nAChRs, ethanol, nicotine, pharmacotherapy, smoking cessation aids, varenicline, mecamylamine
CNS & Neurological Disorders - Drug Targets
Title: Neuronal Nicotinic Acetylcholine Receptors as Pharmacotherapeutic Targets for the Treatment of Alcohol Use Disorders
Volume: 9 Issue: 1
Author(s): S. Chatterjee and S. E. Bartlett
Affiliation:
Keywords: nAChRs, ethanol, nicotine, pharmacotherapy, smoking cessation aids, varenicline, mecamylamine
Abstract: Alcohol use disorders (AUDs) are complex and developing effective treatments will require the combination of novel medications and cognitive behavioral therapy approaches. Epidemiological studies have shown there is a high correlation between alcohol consumption and tobacco use, and the prevalence of smoking in alcoholics is as high as 80% compared to about 30% for the general population. Both preclinical and clinical data provide evidence that nicotine administration increases alcohol intake and nonspecific nicotinic receptor antagonists reduce alcohol-mediated behaviors. As nicotine interacts specifically with the neuronal nicotinic acetylcholine receptor (nAChR) system, this suggests that nAChRs play an important role in the behavioral effects of alcohol. In this review, we discuss the importance of nAChRs for the treatment of AUDs and argue that the use of FDA approved nAChR ligands, such as varenicline and mecamylamine, approved as smoking cessation aids may prove to be valuable treatments for AUDs. We also address the importance of combining effective medications with behavioral therapy for the treatment of alcohol dependent individuals.
Export Options
About this article
Cite this article as:
Chatterjee S. and Bartlett E. S., Neuronal Nicotinic Acetylcholine Receptors as Pharmacotherapeutic Targets for the Treatment of Alcohol Use Disorders, CNS & Neurological Disorders - Drug Targets 2010; 9 (1) . https://dx.doi.org/10.2174/187152710790966597
DOI https://dx.doi.org/10.2174/187152710790966597 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Data Science Approaches to Pharmacogenetics
Current Molecular Medicine The Endocannabinoid Signaling System: A Potential Target for Next- Generation Therapeutics for Alcoholism
Mini-Reviews in Medicinal Chemistry 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Medicinal Chemistry In Vitro and In Vivo Neuroprotective Effects of Etifoxine in β-Amyloidinduced Toxicity Models
CNS & Neurological Disorders - Drug Targets Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Acknowledgement List of the Reviewers
Current Alzheimer Research Antenatal Depression; its Prevalence of Positive Screen and the Associating Risk Factors Including Labor and Neonatal Outcome
Current Women`s Health Reviews Functional Cross-Talk between Adenosine and Metabotropic Glutamate Receptors
Current Neuropharmacology Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Multifaceted Individualities in Pharmacological Treatments of Obesity
Current Clinical Pharmacology Risks Associated with Vortioxetine in the Established Therapeutic Indication
Current Neuropharmacology Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Cariprazine in Bipolar Depression and Mania: State of the Art
CNS & Neurological Disorders - Drug Targets Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology SSRIs, Suicide and Violent Behavior: Is there a Need for a Better Definition of the Depressive State?
Current Drug Safety Analgesia in PACU: Intravenous Opioids
Current Drug Targets Association of <i>FOXP3</i> Polymorphisms with Susceptibility to Multiple Sclerosis: A Meta-Analysis on Genetic Association Studies
Current Pharmacogenomics and Personalized Medicine Dual Cross-Talk between Nitric Oxide and D-Serine in Astrocytes and Neurons in the Brain
Central Nervous System Agents in Medicinal Chemistry The Fascinating Story of Porous Materials
Current Physical Chemistry